Medivation and Astellas expect their oral prostate cancer treatment Xtandi will be available mid-September, following an Aug. 31 FDA approval. The approval came just over one month after the agency accepted the oral treatment for priority review. Xtandi (enzalutamide), a once-daily androgen receptor inhibitor, is indicated for patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel chemotherapy.
Washington Drug Letter